KROS FY 2025 Earnings — Keros Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

KROSKeros Therapeutics, Inc.

$414M

FY 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$244M+6775.0% YoY

Gross Profit

$00.0% margin

Operating Income

$68M27.7% margin

Net Income

$87M35.7% margin

EPS (Diluted)

$2.30

Cash Flow

Operating Cash Flow

$108M

Free Cash Flow

$106M

Stock-Based Comp.

$29M

Balance Sheet

Total Assets

$338M

Total Liabilities

$35M

Stockholders' Equity

$303M

Cash & Equivalents

$287M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$244M	$4M	+6775.0%
Gross Profit	$0	$4M	-100.0%
Operating Income	$68M	-$211M	+132.0%
Net Income	$87M	-$187M	+146.4%